In this non-randomized trial of patients with acute biliary pancreatitis (without cholangitis), patients received either ERCP (within 72 hours) or conservative treatment (at the discretion of the treating physician). Patient characteristics were similar between the groups, and about half received ERCP. The patients were compared in groups by whether or not they had cholestasis (bili>2.3 or common bile duct dilation). Patients with cholestasis had fewer complications with ERCP (adjusted OR=0.35), but there was no significant difference in those without cholestasis. Although not randomized, patients with acute biliary pancreatitis and cholestasis appear to benefit from early ERCP (abstract).
|
July 30, 2009 |
0 
Share This Post
About the Author: Danielle Scheurer
Danielle Scheurer, MD, MSCR, SFHM is a clinical hospitalist and the Chief Quality Officer at the Medical University of South Carolina in Charleston, South Carolina, where she also serves as Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She is also the President of SHM's Board of Directors and previously served as Physician Editor of The Hospitalist, SHM's monthly newsmagazine.
Categories
Related Posts
November 8, 2019 |
0Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
June 29, 2013 |
0This large systematic review found rectal NSAIDs significantly reduced the risk of post-ERCP pancreatitis compared to pancreatic duct stents (abstract).
June 22, 2013 |
0This large population-based cohort found the most common causes of drug induced liver injury to be augmentin and diclofenac, followed by herbal and nutritional supplements (abstract).
Leave A Comment